Newsletter · 2026-07-31 · Ashutosh Agarwal

Bristol Myers Blows Out and the Biotech Buyer Roster Widens - The Biotech Patent Cliff & M&A - Week of July 31, 2026

A synthesis of what biotech and pharma podcasts and the week's earnings said about the patent cliff and M&A for the week of July 31, 2026, including Bristol-Myers beating by 27 percent and doubling its Eliquis growth guide, Argenx's first-ever acquisition, and Lilly's fight to have retatrutide classified as a biologic.

The Biotech Patent Cliff & M&A

Week of July 31, 2026: Bristol-Myers Blows Out, the Buyer Roster Widens

TL;DR

• Bristol-Myers stole earnings week. A cliff-exposed incumbent everyone had written off delivered a monster beat and hiked its full-year profit target by roughly $0.70 a share, with Eliquis, the very drug losing patent protection, up 22% and management doubling its Eliquis growth guide. It also reaffirmed appetite for bolt-on deals. If the cliff is a death sentence, someone forgot to tell BMY this quarter.
• The list of people who can buy your favorite biotech got longer. Argenx, a $50B European antibody maker, did its first-ever acquisition, $2.2B for Forte Biosciences. Podcast analysts used it to make a bigger point: a whole tier of $10-50B biotechs (Vertex, Genmab, Biogen, argenx) is now bidding for the same assets as big pharma. More bidders means higher takeout premiums.
• AbbVie showed the other side of the coin. Revenue beat and Skyrizi/Rinvoq are roaring, but the stock fell because AbbVie trimmed its full-year earnings guide, and the cut was entirely the dilution from buying Apogee. A reminder that even good M&A costs something in the near term. Merck, Pfizer and Lilly report next week.

What's new

1. Bristol-Myers Squibb: the quarter that rewrote the script

Source: verified news flow, Investing.com, Benzinga, and the Q2 2026 earnings call transcript. Reported July 30.

Here is the plain version of why this matters. Bristol-Myers is the poster child for the patent cliff. Its two biggest drugs, the blood thinner Eliquis and the cancer drug Opdivo, are both heading toward the edge, and Eliquis is now subject to Medicare price negotiation. The bear case for years has been: the old drugs fade, the new ones can't grow fast enough to fill the hole, the dividend is at risk. This quarter torched that story.

The numbers: adjusted earnings of $2.04 a share versus about $1.60 expected, a 27.5% beat. Revenue was $12.97B versus roughly $11.74B expected, up 6% year-on-year. Then management raised full-year earnings guidance to $6.75-$7.00, up from $6.05-$6.35, and lifted the revenue target to $49-$50B. That is not a nudge; that is roughly a $0.70-a-share upgrade mid-year.

The kicker is what drove it. Eliquis, the drug that is supposedly dying, did $4.48B in the quarter, up 22%, and management doubled its full-year Eliquis growth guidance to 20-25% from 10-15%. The newer "Growth Portfolio" (the drugs meant to replace the old guard) rose 15% to $7.6B, now about 60% of total revenue, led by Camzyos ($416M, +59%), Breyanzi ($484M, +41%) and Reblozyl ($735M, +29%). Old-guard Revlimid, as expected, fell 49% to $425M.

Why it moves the thesis: On the call, CEO Chris Boerner and CFO David Elkins reaffirmed business development as a strategic priority, targeted, bolt-on M&A and licensing in areas they already know, with about $11.5B in cash, a $5B buyback still authorized, and a "committed" dividend. So the standout cliff-name of the group is simultaneously (a) out-growing its own cliff and (b) telling you it wants to shop. The stock closed up 2.79% at $64.86. For a book, this is the week's biggest number-mover and the strongest single data point yet for the "the cliff is survivable if the pipeline lands" camp.

2. Argenx buys Forte for $2.2B, and the buy-side gets crowded

Podcast: BioCentury This Week, Ep. 379, "Argenx M&A, AI giants and biopharma, catalyst scorecard" (July 28). Speaker: Paul Bananos, BioCentury news editor (journalist/analyst).

Argenx, the Belgian maker of the blockbuster autoimmune drug Vivgart, did its first-ever acquisition: $77 a share in cash, about $2.2B total, for Forte Biosciences. Forte's asset is an antibody against a target called CD122, with early but, in Bananos's words, "promising data in vitiligo and celiac disease," and now moving into alopecia.

The strategy is what analysts call "pipeline in a product," buy one molecule and chase many diseases with it. As Bananos put it, argenx management "pretty much came out and said, you know, that's the playbook and we're looking to repeat it." That is exactly how argenx built Vivgart into a franchise with four approvals and a goal of ten indications by 2030, and Vivgart did $1.5B in revenue last quarter, so a $2.2B deal is, as the BioCentury team noted, "isn't really all that much more than" one quarter of sales for a company with a $50B-plus market cap trading near an all-time high.

Why it moves the thesis, and this is the part worth dwelling on. The BioCentury panel used the deal to make a structural point: the roster of credible acquirers has expanded well beyond big pharma. Their examples, verbatim: "Vertex just made a $10 billion deal" (Crinetics), Genmab "paid $8 billion for Mirus last year," Insightec bought Vega "for more than a billion dollars up front just this month," and Biogen paid "$7 billion for Reata" a couple of years back. One big-pharma dealmaker even told BioCentury this mid-cap tier is "certainly on their radar for the competitive landscape, they're not only looking at their $100 billion-plus peers."

The buy-side roster has grown. For a seller, that means more options and more competition for the asset, which usually means a higher price.

For a patent-cliff-and-M&A newsletter, that is the theme of the year in one deal: the incumbents trying to buy their way out of the cliff are no longer bidding only against each other. They're bidding against a hungry tier of $10-50B biotechs that would rather own a promising single asset than watch it get "lost in a bigger pharma." Bullish for takeout premiums on quality SMID names.

3. AbbVie: a beat that traded like a miss

Source: verified news flow, AbbVie Q2 2026 release (BioSpace), MarketBeat, and the Q2 earnings-call coverage (Investing.com). Reported July 31.

AbbVie is the case study everyone points to for surviving a mega patent cliff. Humira, once the best-selling drug in the world, is now in freefall from biosimilars ($756M this quarter, down 35.9%), and the two replacements, Skyrizi ($5.51B, +24.4%) and Rinvoq ($2.53B, +24.5%), are more than filling the gap. Revenue beat at $16.99B, and AbbVie raised its full-year revenue target to about $67.6B and its Skyrizi guide to $21.7B. The "baton pass" is working.

So why did the stock fall (gapping down more than 4% before settling to roughly 2% lower)? Because AbbVie trimmed its full-year adjusted EPS guidance to $13.87-$14.07. Dig into it and the cut is benign: the ~$0.04 midpoint reduction is $0.14 of dilution from the pending Apogee acquisition, partly offset by $0.10 of operating overperformance. In other words, the underlying business got better; the headline EPS got worse only because AbbVie is buying something. (Reported adjusted EPS of $3.65 was a beat against some Street numbers and a hair light against others, the debate is about the consensus base, not the print.)

Why it moves the thesis: This is the near-term cost of the M&A cure in one line item. Buying Apogee (an IL-13 immunology asset, zumilokibart, aimed at Sanofi/Regeneron's Dupixent) strengthens the post-Humira franchise but dings this year's optics. The Apogee shareholder vote is confirmed for August 11, with close expected in Q3. Barclays nudged its target to $300 from $275 on July 29. The read for a book: don't confuse a guidance trim driven by deal accounting with a deterioration in the business.

4. AstraZeneca: an oncology beat, a pipeline stumble, the $80B dream intact

Source: verified news flow, Investing.com and Interactive Investor. Reported July 27.

AstraZeneca beat on profit, core EPS of $2.63, up 18% at constant currency, versus about $2.48-$2.50 expected, on revenue of $15.4B (roughly in line). It reaffirmed guidance and its ambition of $80B in revenue by 2030, and raised the interim dividend to $1.06. Cancer drugs did the heavy lifting: Tagrisso plus Enhertu grew about 15% to $7.33B, absorbing a sharp fall in the diabetes drug Farxiga (patent loss plus China price cuts). Shares rose about 1.5%.

But the quarter also showed the flip side of a pipeline-heavy strategy. On top of the CARDIO-TTRansform heart-drug failure disclosed July 9 (partner Ionis), AstraZeneca's Ultomiris missed its Phase 3 goal in a transplant complication (a "clear positive" for rival Omeros, which jumped 11%), even as its CLARITY-Gastric01 stomach-cancer drug hit and its Datroway won EU approval in triple-negative breast cancer. CEO Pascal Soriot said on the call he was "disappointed" by the heart-drug outcome.

Why it moves the thesis: AZN is trying to grow its way past its own cliff largely through internal R&D and partnerships rather than big M&A. This quarter says the commercial engine (oncology) is strong enough to keep the $80B target credible, but the pipeline is not free of potholes, a useful counterweight to the "just innovate through the cliff" bull case.

5. The sleeper regulatory story: Lilly's fight to make its next obesity drug a "biologic"

Podcast: On The Pen GLP-1 News, "Retatrutide Biologic Battle: The Story Gets Bigger" (July 28). Host: Dave Knapp (patient advocate/analyst).

This one is under-covered and matters more than its size suggests. Eli Lilly is fighting the FDA over whether its next-generation obesity drug, retatrutide, counts as a "biologic." Why would a company fight to have its own drug reclassified? Because the label determines how long you get to sell it without competition. As Knapp explained: a biologic gets 12 years of market exclusivity versus 5 for a normal small-molecule drug, and when it finally loses protection it faces "biosimilar" competition, which is harder and slower to make than a plain generic, so "much less of a price disruption." It would also lock out the compounding pharmacies that undercut branded pricing. His memorable line: "even old 20-year-old biologics on the market are still commanding five figures a month."

The state of play: Seventh Circuit oral arguments are set for September 24, 2026, in Chicago, 15 minutes a side, "to essentially determine the future of obesity medicine." A lower court agreed with the FDA that retatrutide (40 amino acids) doesn't meet the technical protein definition, but found the FDA's reasoning on a second point ("analogous product") "arbitrary and capricious" and sent it back to the agency.

Why it moves the thesis: Whatever framework the FDA writes "probably" won't stop at retatrutide, as Knapp put it, agencies "generally apply standards consistently." He listed a "laundry list, hundreds of drugs in the pipeline" potentially affected: Viking's VK2735, survodutide, and future triple/quadruple/quintuple agonists, including one from Novo Nordisk. In plain terms: if Lilly wins, the effective patent cliff on the entire next generation of weight-loss drugs stretches much further out. And the fact that Lilly told investors it intends to file a Biologics License Application tells Knapp the company is "fairly confident" it will win. For anyone modeling long-tail GLP-1 economics, September 24 is a date to circle.

The debate: supercycle bull vs. cliff-erosion bear

This week handed both sides fresh ammunition, and it's worth steel-manning each.

The supercycle bull says: look at the tape this week. Bristol-Myers, the ultimate cliff victim, just grew its dying drug 22% and raised guidance by $0.70. AbbVie's Humira replacements are compounding at 24%+. AstraZeneca's oncology engine is funding an $80B target. And the M&A machine that fills the gaps is now bigger than ever, big pharma plus a whole tier of $10-50B biotech buyers. On the GLP-1 side, Morgan Stanley's Terrence Flynn, on Barron's Streetwise "The Everything Pill" (July 31), raised his 2035 GLP-1 forecast to $190B from $150B and called the obesity-drug patent cliff "a manageable risk": Novo's semaglutide is protected to 2031, Lilly's tirzepatide to 2036, formulation patents "run past 2040," and UBS reckons the world's generic factories can only supply 25-30% of GLP-1 demand by 2030 anyway. Host Jack Hough went further, calling GLP-1s "the second biggest profit growth story on Wall Street behind AI," with Lilly on track to generate over $62B of free cash by 2031, roughly $40B more than Novo, money "already being spent on research and tuck-in deals." The cliffs are real, but the growth and the firepower are bigger.

The cliff-erosion bear says: don't confuse a strong quarter with a solved problem. Eliquis growth of 22% is partly a pull-forward ahead of Medicare price cuts, not a permanent state. AbbVie's own guidance trim shows the M&A cure dilutes earnings before it helps them. And the pipeline is not a sure thing: this very week AstraZeneca's heart drug failed, its Ultomiris trial missed, and Novo's ZEUS inflammation trial failed outright, sending the stock down about 9%, three expensive reminders that "just innovate through the cliff" is easier said than done. Even the GLP-1 fortress has cracks: on Dividend Talk's "Q2 2026 Earnings Season" episode (July 25), the hosts made the sharp point that competition erodes pricing power even without a patent expiry: "you can achieve the same outcome with different medicines… so your patent is not so much worth in that case, and that's why they are not charging $1,000 anymore, but $150 or $200." Novo and Lilly are already in an ad war and a price war while both drugs are still patent-protected. And the policy vise keeps tightening: the IRA "pill penalty," Medicare negotiation, the China trial probe, escalating drug tariffs. Value investors keep coming back to the same worry: the cliff names are running to stand still.

Our take: This week tilts us further toward the "quality-growth-through-the-cliff" side, but selectively, and not toward the crowd's favorites. The signal that matters is Bristol-Myers: when the single most cliff-exposed name in the group beats by 27% and doubles the growth guide on the drug it's supposedly losing, the market's blanket "cliff equals doom" discount on incumbents looks too harsh. The setup we like is a cheap incumbent with a growth portfolio the market isn't paying for (BMY fits; AbbVie's Apogee-driven sell-off is a similar opportunity if you can look through the deal accounting). What we'd avoid is paying up for the obvious winner into a binary week: Lilly reports Wednesday, and the stock already carries a supercycle multiple (about 35x versus Novo's 15-16x). The most underpriced thing on our screen is optionality that isn't in consensus at all: the retatrutide "biologic" ruling on September 24, which could quietly extend the GLP-1 cliff by years, and the widening buyer roster, which should keep a bid under quality SMID takeout targets regardless of what any one big-cap prints.

Stocks in play

Read-throughs

• The widening buyer roster is the SMID-cap put. The argenx/Forte deal, on top of Vertex/Crinetics ($10B), Genmab/Mirus ($8B) and Insightec/Vega (>$1B), says quality single-asset and platform biotechs now have multiple credible bidders. That should keep a floor under takeout premiums and support SMID sentiment (and XBI) even in weeks when the big-caps are quiet, the demand for assets is structural, not dependent on any one acquirer.
• Bristol-Myers reaffirming bolt-on M&A plus AbbVie closing Apogee means the deal machine is running on both ends. Cliff-exposed incumbents are both raising numbers and spending to defend them. Bankers and CROs benefit from the volume; the read for targets in immunology (post-Apogee) and cardiometabolic (post-Crinetics) is that the strategic buyers are actively shopping those exact aisles.
• This week's three pipeline failures (AZN CARDIO-TTRansform, AZN Ultomiris, Novo ZEUS) are a tax on the "innovate through the cliff" model. They also created discrete read-throughs: Omeros +11% on the Ultomiris miss; IL-6 and inflammation names (Monte Rosa, BioAge) hit on ZEUS. The lesson for a book: internal-R&D cliff defense carries binary risk that external M&A (paying up for de-risked assets) is partly meant to avoid, which is why the buyer roster keeps growing.
• The retatrutide "biologic" case is a hidden lever on the entire GLP-1 complex. If the September 24 appeal ultimately pushes FDA toward a broader "biologic" definition, the next generation of weight-loss drugs (Viking's VK2735, survodutide, Novo/Lilly triple-agonists) could inherit 12-year exclusivity and biosimilar-only competition, a materially softer cliff than the market assumes. Bullish long-tail for the obesity franchise owners; bearish for compounders and generic hopefuls.
• Policy overhang is still building, quietly. Pfizer conceded to the House China committee (no more trials in Xinjiang or PRC military hospitals, per Fox News and Healio), and Chairman Moolenaar's proposed BINSA bill would restrict outbound biotech investment (explicitly citing BMS's $15.2B Hengrui deal). Separately, generic-drug tariffs are scheduled to hit 100% in 2028 and 200% in 2029 after a two-year grace period (AJMC and Supply Chain Dive), and CMS's rule codifying 2029 Medicare price negotiation is open for comment until August 17. None of this is acute yet, but it's the slow tightening that shapes where the M&A dollars flow (toward US-manufacturable, biologic-protected, negotiation-resistant assets).

What changed vs. last week

• Novo and Lilly lawsuit: Escalated as promised. Last week it was the newly filed advertising suit; this week Novo notified the court it intends to file a preliminary injunction on August 17 to pull Lilly's ads and fund corrective advertising. Lilly has not counter-sued, it rejected the cease-and-desist, added fine-print disclosure, and vowed to defend. Still a civil false-advertising fight, no FDA or FTC involvement.
• The "rising biotech buyer" theme graduated from a value-investor aside to the week's headline deal. Last week Telltales framed the "growth-allocator vs defensive-replacer" debate (Lilly/Vertex vs Pfizer). This week the argenx/Forte deal and BioCentury's panel turned that into a concrete structural call: the buy-side tier below big pharma is now a real force.
• Earnings runway delivered. Last week's open item was "watch AZN 7/27, BMY 7/30, ABBV 7/31 for M&A signals." Result: AZN beat but stumbled on pipeline; BMY blew out and reaffirmed bolt-on appetite; ABBV beat on revenue but trimmed EPS guide on Apogee dilution.
• Retatrutide filing slipped to Q1 2027 (from end-2026), but it's a manufacturing and quality-data timing issue, not an efficacy problem. Trials hit their weight-loss and cardiometabolic endpoints.
• New pipeline failure to log: Novo's ZEUS trial (ziltivekimab, IL-6 inhibitor) missed its primary heart-outcomes endpoint (hazard ratio 0.99), stock -9%. Adds to the AZN CARDIO-TTRansform failure carried over from July 9 (full data still due at ESC late August).
• Deal calendar tightened: AbbVie/Apogee vote now firmly August 11; Vertex/Crinetics on track for Q3; Sangamo's bankruptcy auction has firm dates, bid deadline Aug 4, auction Aug 10, sale hearing Aug 20 (Lilly and Astellas remain the stalking-horse bidders); RVMD's pancreatic-cancer drug is on an accelerated FDA review that could decide within the quarter.